NASDAQ · SERVICES-MEDICAL LABORATORIES · LARGE CAP
RadNet, Inc. RDNT
17 fiscal years on record · USD · FY2025 reported · SEC filings only
In brief
What this company does
Written from the business description in RadNet, Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 2 March 2026. Every sentence was checked against that document before publication.
Growth
USD 2.0B
Revenue, FY2025 · full 17-year series below
Revenue $B
Net income $B
FY2025 · Revenue 2.0 · Net income -0.0
Compound annual growth
Revenue compounded at +13.7% a year over five years.
Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.
Profitability
1 cents
of every revenue dollar became profit
Operating margin
Net margin
FY2025 · Operating 3.0% · Net 0.8%
ROE
FY2025 · ROE -1.9%
Each USD of equity lost 2 cents this year.
The 17-year record
17 fiscal years
Every figure from documents filed with the SEC · USD
row low → row highnegative
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue $B | 2.0 | 1.8 | 1.6 | 1.4 | 1.3 | 1.1 | 1.2 | 1.0 | 0.9 | 0.9 | 0.8 | 0.1 | 0.1 | 0.1 | 0.0 | 0.0 | 0.5 |
| Operating income $B | 0.1 | 0.1 | 0.1 | 0.0 | 0.1 | 0.0 | 0.1 | 0.0 | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| EBITDA $B | 0.2 | 0.2 | 0.2 | 0.2 | 0.2 | 0.1 | 0.2 | 0.1 | 0.1 | 0.1 | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | · |
| Income tax $B | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | −0.1 | 0.0 | 0.0 | 0.0 |
| Net income $B | −0.0 | 0.0 | 0.0 | 0.0 | 0.0 | −0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | −0.0 |
| Free cash flow $B | · | · | · | · | · | · | 0.0 | 0.0 | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| EPS, diluted $ | −0.25 | 0.04 | 0.05 | 0.17 | 0.46 | −0.29 | 0.29 | 0.66 | 0.00 | 0.15 | 0.17 | 0.03 | 0.05 | 1.52 | 0.19 | −0.35 | −0.06 |
| Dividend / sh $ | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · |
| Payout % | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · |
| ROE % | −1.9 | 0.4 | 0.6 | 3.8 | 12.5 | −9.4 | 10.6 | 34.2 | 0.1 | 16.3 | 34.9 | 279.9 | · | · | · | · | · |
| Shares out B | 0.07 | 0.07 | 0.07 | 0.06 | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 | · |
Slide the table for earlier years · "·" marks a figure not available in our data for that year.
Provenance
Company facts, as filed
How we verify · 0 failures in 65 reconciliationsAUDITED
Reconciled in 17 of 19 fiscal years. 19 checks could not be computed.
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityServices-Medical Laboratories
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsDecember 31
Data on record since2009